GVK Biosciences

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status:
European Commission final decision


GVK Biosciences: European Medicines Agency confirms recommendation to suspend medicines over flawed studies

Medicines considered critically important for patients to remain available

On 21 May 2015, the European Medicines Agency (EMA) confirmed its recommendation to suspend a number of medicines for which authorisation in the European Union (EU) was primarily based on clinical studies conducted at GVK Biosciences in Hyderabad, India. This is the outcome of a re-examination requested by marketing authorisation holders for seven of the medicines concerned.

EMA's Committee for Medicinal Products for Human Use (CHMP) had adopted its original recommendation in January 2015 following an inspection of GVK Biosciences' site at Hyderabad by the French medicines agency (ANSM) that raised concerns about how GVK Biosciences conducted studies at the site on behalf of marketing authorisation holders.

The inspection revealed data manipulations of electrocardiograms (ECGs) during the conduct of some studies of generic medicines, which appeared to have taken place over a period of at least five years. Their systematic nature, the extended period of time during which they took place and the number of members of staff involved cast doubt on the integrity of the conduct of trials at the site generally and on the reliability of data generated.

During the re-examination, the CHMP concluded that concerns about reliability of the clinical studies remain and therefore maintained its recommendation of January 2015 to suspend medicines for which no supporting data from other studies were available. This is with the exception of one medicine included in the re-examination for which concerns about studies were addressed. This medicine was removed from the list of medicines recommended for suspension.*

As a result of the CHMP's January 2015 opinion and the re-examination, around 700 pharmaceutical forms and strengths of medicines studied at the Hyderabad site were recommended for suspension. For around 300 other pharmaceutical forms and strengths, sufficient supporting data from other sources had been provided; these medicines will therefore remain on the market in the EU.

The PDF icon updated list of medicines for which the CHMP recommended suspension is available on the EMA website.

The CHMP noted that there is no evidence of harm or lack of effectiveness linked to the conduct of studies by GVK Biosciences at Hyderabad. Some of these medicines may remain on the market in some countries if they are of critical importance for patients because alternatives cannot meet patients' needs.

The decision on whether a medicine is critical for patients lies with the national authorities of EU Member States. For medicines that are considered critical, companies are given 12 months to submit additional data.

EMA and national authorities work closely with international partners to ensure that studies underpinning marketing authorisations in the EU are carried out to the highest standards and that the companies involved comply fully with all aspects of Good Clinical Practice (GCP).

The CHMP's recommendation was sent to the European Commission for a legally binding decision. The Commission has issued its decision which applies to all Member States irrespective of whether or not they have taken interim measures to suspend medicines.

* Bivolet (nebivolol) 5 mg tablets (marketing authorisation holder: Neo Balkanika EOOD); the product has now been removed from the list of medicines recommended for suspension.

Key facts

Approved name
GVK Biosciences
International non-proprietary name (INN) or common name
  • esomeprazole magnesium
  • candesartan cilexetil
  • nebivolol
  • desloratadine
  • donepezil
  • repaglinide
  • candesartan
  • esomeprazole
  • alendronic acid
  • ropinirole
  • cefpodoxime
  • quetiapine
  • trimetazidine
  • bosentan
  • tramadol
  • paracetamol
  • escitalopram
  • trimetazidine hydrochloride
  • entacapone
  • valsartan
  • hydrochlorothiazide
  • donepezil hydrochloride
  • ropinirole hydrochloride
  • clopidogrel hydrochloride
  • escitalopram oxalate
  • metformin hydrochloride
  • trimetazidine dihydrochloride
  • rizatriptan benzoate
  • metformin
  • fluconazole
  • eletriptan
  • rizatriptan
  • ebastine
  • ibuprofen
  • desmopressin
  • aciclovir
  • levetiracetam
  • irbesartan
  • venlafaxine
  • ciprofloxacin
  • cefpodoxime proxetil
  • tacrolimus
  • fexofenadine hydrochloride
  • phenoxymethylpenicillin
  • amlodipine besilate
  • metoclopramide
  • clopidogrel
  • levodopa
  • carbidopa
  • entacapone
  • atorvastatin
  • telmisartan
  • clindamycin hydrochloride
  • metoclopramide hydrochloride
  • clonazepam
  • clobazam
  • dexamethasone
  • thiamine hydrochloride
  • tramadol hydrochloride
  • pioglitazone
  • dipyridamole
  • fexofenadine
  • amlodipine
  • pantoprazole
  • hydrocortisone
Reference number
Article 31 referrals

This type of referral is triggered when the interest of the Union is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.

European Commission final decision
Opinion date
EC decision date

All documents

Document description

  • Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
  • Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents are sometimes available:

How useful was this page?

Add your rating
2 ratings